NimbleGen gives Roche entry into microarrays
This article was originally published in Clinica
Executive Summary
Roche Diagnostics is poised to enter the microarray systems market after signing a definitive agreement to purchase high-density DNA microarray developer NimbleGen Systems in a $272.5m deal. The merger will see NimbleGen (Madison, Wisconsin) develop and market array systems through Roche's diagnostics arm Roche Applied Science (RAS), whilst also expanding its portfolio to include higher density arrays, integrated instrument systems and related reagents for advanced genome analysis.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.